Department of Surgery, Division of Trauma and Surgical Critical Care, University of South Alabama Medical Center, 2451 Fillingim St, Mobile, AL 36617, USA.
Am J Surg. 2013 Mar;205(3):255-8; discussion 258. doi: 10.1016/j.amjsurg.2012.10.011. Epub 2013 Jan 30.
The treatment of ventilator-associated pneumonia (VAP) secondary to methicillin-resistant Staphylococcus aureus (MRSA) remains controversial.
We performed a review of all blunt trauma patients diagnosed with MRSA VAP from June 2005 to June 2011. VAP for the first 3 years was diagnosed by sputum aspiration and treated with vancomycin. For the last 3 years of the study period, VAP was diagnosed with bronchoalveolar lavage and treated with linezolid.
MRSA VAP patients treated with vancomycin had an average hospital length of stay (LOS) of 49 days (range 9-99 days), an average intensive care unit (ICU) LOS of 43 days (range 6-98 days), and average ventilator days of 34.4 (range 3-76 days). Seventeen MRSA VAP patients treated with linezolid had an average hospital LOS of 27 days (range 11-61), an average ICU LOS of 22 days (range 10-42) days, and average ventilator days of 16.6 (range 2-42).
Trauma patients who develop MRSA VAP appear to have fewer ventilator days and shorter ICU and hospital LOS when treated with linezolid.
耐甲氧西林金黄色葡萄球菌(MRSA)引起的呼吸机相关性肺炎(VAP)的治疗仍存在争议。
我们对 2005 年 6 月至 2011 年 6 月期间所有诊断为 MRSA VAP 的钝性创伤患者进行了回顾性分析。前 3 年,VAP 通过痰抽吸进行诊断,并使用万古霉素进行治疗。在研究期间的最后 3 年,VAP 通过支气管肺泡灌洗进行诊断,并使用利奈唑胺进行治疗。
使用万古霉素治疗的 MRSA VAP 患者的平均住院时间(LOS)为 49 天(范围为 9-99 天),平均重症监护病房(ICU)LOS 为 43 天(范围为 6-98 天),平均呼吸机使用天数为 34.4 天(范围为 3-76 天)。17 例使用利奈唑胺治疗的 MRSA VAP 患者的平均住院时间为 27 天(范围为 11-61 天),平均 ICU LOS 为 22 天(范围为 10-42 天),平均呼吸机使用天数为 16.6 天(范围为 2-42 天)。
与使用万古霉素治疗相比,发生 MRSA VAP 的创伤患者使用利奈唑胺治疗似乎可减少呼吸机使用天数,缩短 ICU 和住院时间。